CALI: CalciMedica Corp Growth-Adjusted Market Cap to Net Income
CalciMedica, Inc. (CALI) is currently in the clinical testing phase, which temporarily limits its revenue. However, the unique drug Auxora provides significant pricing power within intensive care units. Growth is expected to be driven by new pancreatitis data and partnerships by 2026. The current PEG ratio reflects the capitalization dynamics relative to earnings, with the current value standing at 0.00.
Metric breakdowns and analytics for CalciMedica, Inc. (CALI)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
- business earnings and investment ratios data:
CALI - Company Net Income|Expected Profit CalciMedica, Inc.|CALI - P/E Multiple|Projected Price to Earnings calcimedica.com|CALI - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio CalciMedica Corp|CALI - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months CalciMedica|CALI - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months calcimedica.com|CALI - Earnings growth in current year|Projected earnings per share growth rate for next year CalciMedica, Inc.
- total revenue and sales volume data:
General company analysis:CALI - CalciMedica Inc
An investor determines an asset's margin of safety by comparing the P/E market multiple with earnings expansion rates, where a value below one signals fundamental undervaluation. For CalciMedica, Inc. (CALI), the high scalability of proprietary drugs coupled with low synthesis costs makes the current PEG ratio a key indicator of market capitalization growth potential within the biotechnology segment.
Competing companies
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Pharma - PEG Multiple|Pharvaris Pharma (PHVS) - Price/Earnings to Growth Multiple|ABCL: PEG Multiple|tourmalinebio.com (TRML) - PEG Multiple|Price/Earnings to Growth Ratio Precigen|Price/Earnings to Growth Ratio PHAR|PEG Multiple NKTR|Price/Earnings to Growth Multiple Upstream Pharma UPB|PEG Multiple ZBIO (Zenas Biopharma Inc)|Growth-Adjusted Market Cap to Net Income immunome.com (IMNM)|GOSS - Price/Earnings to Growth Ratio|KalVista Pharma (KALV) - Price/Earnings to Growth Multiple|SEPN: PEG Multiple|Price to Earnings Adjusted for Growth Rate Pieris Corp (PVLA)|SVRA (Savara Inc.) - PEG Multiple|Growth-Adjusted P/E Ratio RIGL (rigel.com)|PEG Multiple ANAB|Growth-Adjusted Market Cap to Net Income Astria Therapeutics Inc|PEG Multiple ENGN (enGene Bio)|RAPT - Price/Earnings to Growth Multiple|Aerovate - PEG Multiple|ACRS - PEG Multiple|KYTX (Kyverna Therapeutics, Inc.) - Price/Earnings to Growth Multiple|Tiziana Life Sciences Ltd. - Growth-Adjusted Payback Ratio|CABA (Cabaletta Bio, Inc) - PEG Multiple|Ventyx Biosciences, Inc (VTYX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Theratechnologies Inc. (THTX)|avalotx.com - Growth-Adjusted P/E Ratio|PEG Multiple ELDN (Eledon Pharmaceuticals, Inc.)|AGEN - Price/Earnings to Growth Multiple|CLYM: Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income zurabio.com ZURA|ATYR: PEG Multiple|Price/Earnings to Growth Multiple Adagene Inc.|IMA (ImageneBio) - PEG Multiple|PEG Multiple Shattuck Therapeutics|Price/Earnings to Growth Ratio Equillium, Inc. (EQ)|Price/Earnings to Growth Ratio CNTB (connectbiopharm.com)|PEG Multiple IMUX (Immunic)|Growth-Adjusted Market Cap to Net Income Atara Biotherapeutics, Inc. (ATRA)|IFRX - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio XFOR|ACET: PEG Multiple|Celularity - Growth-Adjusted Payback Ratio|INMB (INmune Bio, Inc.) - PEG Multiple|PEG Multiple barinthusbio.com|Price/Earnings to Growth Ratio Kezar Life Sciences, Inc. (KZR)|SABS (SAB Biotherapeutics Inc.) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Akari Therapeutics plc AKTX|ENLV - Price/Earnings to Growth Multiple|Q32 Bio Corp - PEG Multiple|GOVX - PEG Multiple|EDSA (Edesa Biotech) - Price/Earnings to Growth Multiple|iBio Inc - Growth-Adjusted Payback Ratio|CARM (Carisma Therapeutics Inc) - PEG Multiple|XTL Bio (XTLB) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Bolt Biotherapeutics (BOLT)|Price/Earnings to Growth Multiple hcwbiologics.com HCWB|Price/Earnings to Growth Ratio Aptevo Therapeutics Inc. APVO|AIM - Price/Earnings to Growth Multiple|ADTX: Price/Earnings to Growth Multiple|GRI - PEG Multiple|XORTX Therapeutics Inc. (XRTX) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio HIND|REVB (Revelation Biosciences, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Indaptus Therapeutics Inc INDP|PEG Multiple SCNI|Price/Earnings to Growth Multiple affimed.com AFMD|PEG Multiple ALLK (Allakos)|PEG Multiple HOOKIPA Pharma, Inc. HOOK|IGMS - Price/Earnings to Growth Ratio|ITOS: Price/Earnings to Growth Ratio|OCEA: PEG Multiple|Price/Earnings to Growth Multiple TC BioPharm Ltd|THRD (Third Harmonic Bio) - PEG Multiple
